Md. Shohag Hossain

Mr. Md. Shohag Hossain

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Alomgir HossainAlomgir Hossain
Alomgir Hossain
FJFaria Tasnin Joti
Faria Tasnin Joti
Md. Shohag HossainMd. Shohag Hossain
Md. Shohag Hossain
Abdullah Al-NomanAbdullah Al-Noman
Abdullah Al-Noman
CCChomong Thowing Chomong
Chomong Thowing Chomong
Md Azizul HaqueMd Azizul Haque
Md Azizul Haque
Background: Dengue virus (DENV) is the fatal pathogenic arthropod-borne virus (arboviruses) that belongs to the Flaviviridae family, which transmits to humans through mosquito bites from infected Aedes aegypti and Aedes albopictus mosquitoes or maternal-fetal transmission. Despite antigenic differences, the four serotypes of DENV (DENV-1 to DENV-4) share 65–78% of their genome. Non-structural (NS) proteins amongst serotypes show analogous functions. Among NS proteins, NS3 and NS5 are frequently used as targets for antiviral drugs due to their multifunctional roles. Methods: To identify potential inhibitors of DENV, we created a phytochemical library of 898 compounds derived from 17 medicinal plants recognized for their medicinal and antiviral properties. The phytochemicals library has been docked against the target proteins. Phytochemicals with a docking score greater than −8.0 kcal/mol were selected for further evaluation using a machine learning approach. Further, molecular dynamics (MD) simulations were conducted to evaluate the root mean square deviation, root mean square fluctuation, solvent-accessible surface area, radius of gyration, and hydrogen bond count of the compounds. Results: From the docking results, Silibinin, Rubiadin, and Ellagic acid showed binding affinities of −8.5, −8.3, and −8.2 kcal/mol, respectively, for NS3, and NSC 640467, Bisandrographolide A, and Andrographidin A showed binding affinities of −9.3, −10.1, and −9.3 kcal/mol, respectively, for NS5 target proteins. These compounds exhibited strong interactions with target proteins. MD simulation results confirmed the stable formation of protein–ligand complexes. Further, absorption, distribution, metabolism, excretion, and toxicity (ADMET) and bioactivity predictions confirmed their pharmacological safety. Conclusions: Despite global public health concerns, DENV still lacks specific drug treatments. Our identified new drug candidates might help for developing effective antiviral inhibitors against the DENV. However, further confirmation is needed through in vivo and in vitro research.

24 November 2025 in Journal of Physics and Chemistry of Solids
Verified
Journal Article
Closed access
EREkhtiar Rahman
Ekhtiar Rahman
Md. Shohag HossainMd. Shohag Hossain
Md. Shohag Hossain
NANabil Ahmed
Nabil Ahmed
FJFaria Tasnin Joti
Faria Tasnin Joti
Abdullah Al-NomanAbdullah Al-Noman
Abdullah Al-Noman
Mohammad Nurul MatinMohammad Nurul Matin
Mohammad Nurul Matin

13 October 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BBBishal Budha
Bishal Budha
GCGourab Basu Choudhury
Gourab Basu Choudhury
Md. Shohag HossainMd. Shohag Hossain
Md. Shohag Hossain
AAArjun Acharya
Arjun Acharya
FLT3 (FMS-like tyrosine kinase 3), a receptor tyrosine kinase, is frequently mutated in acute myeloid leukemia (AML), a hematologic malignancy marked by aggressive proliferation, poor prognosis, and high relapse rates. Although FDA-approved FLT3 inhibitors exist, their clinical efficacy is often undermined by resistance and off-target effects, underscoring the critical necessity for more effective and selective agents. Here, we employed a structure-based computational approach combining pharmacophore screening via Pharmit and the MolPort compound library to identify novel FLT3 inhibitors. Pharmacophore modeling, virtual screening, and docking identified two promising leads, MolPort-002-705-878 and MolPort-007-550-904, with binding affinities of –11.33 and –10.66 kcal/mol, correspondingly. These compounds were further evaluated using molecular dynamics (MD) simulations to assess binding stability, density functional theory (DFT) calculations to explore electronic reactivity, and ADMET profiling to examine pharmacokinetic and toxicity parameters. MD results, including principal component analysis (PCA) and free energy landscape (FEL) mapping, supported the integrity of the FLT3–lead complexes, with MM/GBSA binding free energies ( ΔG ) of –39.23 kcal/mol and –27.03 kcal/mol for MolPort-002-705-878 and MolPort-007-550-904, respectively. DFT analysis indicated favorable frontier molecular orbital energies and reactivity indices, characterized by a low HOMO–LUMO energy gap and a reactive dipole moment. ADMET predictions indicated acceptable drug-likeness and low toxicity, pending further experimental confirmation. This integrated in silico pipeline highlights the therapeutic potential of these molecules as next-generation FLT3 inhibitors and offers a scalable strategy for targeted AML therapeutics.

27 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
BBBishal Budha
Bishal Budha
GCGourab Basu Choudhury
Gourab Basu Choudhury
Md. Shohag HossainMd. Shohag Hossain
Md. Shohag Hossain
AAArjun Acharya
Arjun Acharya
FLT3 (FMS-like tyrosine kinase 3), a receptor tyrosine kinase, is frequently mutated in acute myeloid leukemia (AML), a hematologic malignancy marked by aggressive proliferation, poor prognosis, and high relapse rates. Although FDA-approved FLT3 inhibitors exist, their clinical efficacy is often undermined by resistance and off-target effects, underscoring the critical necessity for more effective and selective agents. Here, we employed a structure-based computational approach combining pharmacophore screening via Pharmit and the MolPort compound library to identify novel FLT3 inhibitors. Pharmacophore modeling, virtual screening, and docking identified two promising leads, MolPort-002-705-878 and MolPort-007-550-904, with binding affinities of −11.33 and −10.66 kcal/mol, correspondingly. These compounds were further characterized through molecular dynamics (MD) simulations, incorporating Principal Component Analysis (PCA), free energy landscape (FEL) analysis, density functional theory (DFT) calculations, and ADMET profiling. MD results supported the integrity of the FLT3–lead complexes; DFT revealed favorable reactivity, and ADMET predictions indicated drug-likeness with low toxicity, pending experimental confirmation. This integrated in silico pipeline highlights the potential of these molecules as next-generation FLT3 inhibitors and offers a scalable strategy for targeted AML therapeutics.